Related Articles
Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy
RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION
SUBCUTANEOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN PREVENTS CHEMOTHERAPY-RELATED ANEMIA IN PATIENTS WITH ADVANCED CANCER
Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients